UK authority accuses Actavis UK and Concordia of illegal agreement

Home/Policies & Legislation | Posted 07/04/2017 post-comment0 Post your comment

The UK’s Competition and Markets Authority (CMA) alleged that pharmaceutical companies, Actavis UK and Concordia, entered into illegal agreements that allowed them to increase and maintain high prices of hydrocortisone tablets. 

Contract Tender V13H30

In their press release, the CMA stated that Actavis UK, recently acquired by Intas Pharmaceuticals [1] and Concordia, entered into agreements in which Actavis UK offered incentives to Concordia, persuading them not to enter the market with its own version of hydrocortisone tablets. This is reported to have taken place between January 2013 and June 2016.

These allegations follow previous claims made by the CMA that were reported in December 2016. Here, they stated that the cost of 10 mg hydrocortisone tablets increased by 12,000%, from GBP 0.70 to GBP 88.00 a tablet between April 2008 and March 2016. Over the same period, the 20 mg packs went from GBP 1.07 to GBP 102.74 per pack, a 9,500% rise. Prior to April 2008, the National Health Service (NHS) spent about GBP 522,000 a year on hydrocortisone tablets. As a result of price rise, by 2015, the NHS was paying GBP 70 million for the tablets [2].

In their statement of objections released on 3 March 2017, the CMA announced that they provisionally found that both companies broke competition law by coming to anti-competitive agreements. Here, Actavis UK is also accused of abusing its dominant position in the market to persuade rival company Concordia to delay its independent entry of hydrocortisone tablets to the market. It is reported that Actavis UK also supplied Concordia with low price 10 mg tablets that they could then sell on to customers, including the NHS, in the UK. This meant that Actavis UK maintained a monopoly that allowed prices to soar and denied the NHS access to cheaper options, thus causing a burden on the taxpayer and patients. It is reported that, Andrew Groves, CMA Senior Responsible Officer said, ‘We allege these agreements were intended to keep Actavis UK as the sole supplier of a drug relied on by thousands of patients – and in a position which could allow it to dictate and prolong high prices’.

Related article
Teva sells Actavis UK and Ireland generics business to Intas

1. GaBI Online - Generics and Biosimilars Initiative. Intas enters top 20 generics firms through Actavis purchase []. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Apr 7]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative.UK competition authority accuses Actavis of overcharging NHS []. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Apr 7]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
PDUFA VI: FDA could promote generics competition
47 MD001813
Home/Policies & Legislation Posted 29/07/2022
House bill passes FDA funding fees but conflicts with Senate bill
User Fee V13H23
Home/Policies & Legislation Posted 15/07/2022
US Senate clarifies status of interchangeable biosimilar exclusivity
Interchangeability V18K30
Home/Policies & Legislation Posted 27/05/2022
Nomenclature of biologicals and biosimilars in Peru
02 AA010638
Home/Policies & Legislation Posted 20/05/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010